Welcome to the e-CCO Library!

P313: Within 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses
Year: 2022
Source: ECCO'22
Authors: Rabinowitz, K.M.(1,2);Navon, M.(3);Edelman-Klapper, H.(1,4);Zittan, E.(5,6);Bar-Gil Shitrit, A.(7,8);Goren, I.(1,4);Avni-Biron, I.(1,4);Ollech, J.E.(1,4);Lichtenstein, L.(9);Banai-Eran, H.(1,4);Yanai, H.(1,4);Snir, Y.(1,4); Pauker, M.H.(1);Friedenberg, A.(1);Levy-Barda, A.(10);Segal, A.(11);Broitman, Y.(1,4);Maoz, E.(12);Ovadia, B.(13);Aharoni Golan, M.(1);Shachar, E.(4,14);Ben-Horin, S.(4,14);Perets, T.T.(15,16);Ben Zvi, H.(17);Eliakim, R.(4,14);Barkan, R.(1);Goren, S.(18);Krugliak, N.(3);Werbner, M.(19);Alter, J.(20);Dessau, M.(20);Gal-Tanamy, M.(19);Cohen, D.(18);Freund, N.T.(3);Dotan, I.(1,4);
Created: Friday, 11 February 2022, 3:52 PM
P314 C-Reactive protein is associated with depression and anxiety in patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Rodriguez, J. Karpin, C. Traboulsi, V. Rai, D. Rubin

Created: Thursday, 30 January 2020, 10:12 AM
P314: Elderly onset is associated with low efficacy of anti-TNF treatment in Bio-naïve IBD patients: A multicenter cohort study by the Osaka Gut Forum
Year: 2022
Source: ECCO'22
Authors: Amano, T.(1);Shinzaki, S.(1);Asakura, A.(1);Tashiro, T.(1);Otake, Y.(1);Tani, M.(1);Yoshihara, T.(1);Inoue, T.(1);Takehara, T.(1);
Created: Friday, 11 February 2022, 3:52 PM
P314: Long-term fate of the excluded rectum in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Yzet*1, G. Kassim2, N. Nair2, J-F. Colombel2, D. B. Sachar2

Created: Friday, 22 February 2019, 9:41 AM
P314: Management of perianal disease in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Algaba A.*1, Rubín de Célix C.1, Guerra I.1, Serrano A.2, Pérez-Viejo E.2, Aullό C.3, Hernández-Tejero M.1, Granja A.1, Bermejo F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P314: Microscopic appendicitis in ulcerative colitis: Feasibility of ultrasonographic diagnosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Reijntjes, M.(1)*;Pruijt, M.(2);Visser, E.(1);de Voogd, F.(2);d'Haens, G.R.(2);Mookhoek, A.(3);Gecse, K.B.(2);Buskens, C.J.(1);Bemelman, W.A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P314: MRI fistulography
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Sahnan1*, S.O. Adegbola1, P.J. Tozer1, A. Gupta2, J. Warusavitarne1, O.D. Faiz1, A.L. Hart3, R.K. Phillips1, P.F. Lung2

Created: Thursday, 21 February 2019, 9:14 AM
P314: Proposal for an anti-tumour necrosis factor–exit strategy based on trough serum level
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

U. Helwig*1, F. Lutter1, N. Koppka2, S. Schreiber3

Created: Friday, 22 February 2019, 9:49 AM
P314: TNF gene activation used as criterion to discontinue biologic therapy – A patient series introducing the NovaPrime TNF kit
Year: 2021
Source: ECCO'21 Virtual
Authors: Goll, R.(1);Kay-Martin, J.(1);Viola, A.(2);Paulssen, E.(1);Moe, Ø.K.(1);Cui, G.(3);Fries, W.(2);Florholmen, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P315 Short-chain fatty acid profile in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Oliveira, L. Yukie Sassaki, A. Elisa Valencise Quagli, J. Ribeiro de Barros

Created: Thursday, 30 January 2020, 10:12 AM
P315: Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Michetti*1, L. Peyrin-Biroulet2, M. S. Silverberg3, E. Louis4, J. Weinman5, J. Sommer6, J. Petersson7, B. Pappalardo7, P. Nurwakagari8

Created: Friday, 22 February 2019, 9:49 AM
P315: Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Collins M.*1, Michot J.-M.2, Danlos F.-X.2, Champiat S.2, Mussini C.1, Soularue E.1, Mateus C.3, Loirat D.4, Buisson A.5, Rosa I.1,6, Lambotte O.1, Laghouati S.2, Voisin A.-L.2, Soria J.-C.2, Marabelle A.2, Robert C.2, Carbonnel F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P315: High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study
Year: 2022
Source: ECCO'22
Authors: Karki, C.(1);Sharpe, E.(2);Hantsbarger, G.(3);Lee, K.(4);Perovic, M.(5);Raven, L.(6);Sajak-Szczerba, M.(7);Silber, A.(2);Yoon, A.(8);Tozer, P.(9);
Created: Friday, 11 February 2022, 3:52 PM
P315: Molecular screening for Lynch syndrome in IBD colorectal cancer
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Anele1*, G. Worley1, D. Georgiou2, M. Moorghen1, O. Faiz1, A. Latchford1

Created: Thursday, 21 February 2019, 9:14 AM
P315: Population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Tatosian, D.(1);Shen, J.(1);Chen, L.(1);Lavigne, J.(2);Teuscher, N.(3);Harris, S.(1);Chitkara, D.(1);Tirucherai, G.S.(1);Marta, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P315: Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Salas*1, K. M. Grebe2, N. Powell3, J. Panés1, J. W. Davis4, F. Hong4, Y. Pang4, A. A. Suleiman5, K. Wallace4, B. G. Feagan6

Created: Friday, 22 February 2019, 9:41 AM
P315: The characteristics and severity of pediatric ulcerative proctitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Müller, K.(1)*;Dohos , D.(2);Imrei, M.(3);Gombos, E.(3);Szentannay , J.(3);Szabó, A.(3);Oberfrank, M.(4);Karoliny, A.(5);
Created: Friday, 14 July 2023, 11:05 AM
P316: A study on the impact of diagnosis on the level of exercise amongst patients with IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Schembri1, K. Gatt1*, K.H. Katsanos2, D.K. Christodoulou2, D. Balomenos2, K. Karmiris3, C. Pontas4, U. Kopylov5, I. Koutroubakis6, K. Foteinogiannopoulou6, A. Fábián7, T. Molnár7, D. Zammit1, P. Ellul1, G.J. Mantzaris4

Created: Thursday, 21 February 2019, 9:14 AM
P316: Human neutrophil elastase derived fragment of calprotectin (S100a9) is a serum biomarker (CPa9-HNE) for monitoring of anti-TNFα treatment response in Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Mortensen, J.(1);Karsdal, M.A.(1);Grønbæk, H.(2);Hvas, C.L.(2);Dige , A.(2);Bay-Jensen, A.C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM